Integer (NYSE:ITGR) Hits New 1-Year High - What's Next?

Shares of Integer Holdings Co. (NYSE:ITGR - Get Free Report) reached a new 52-week high during trading on Tuesday . The company traded as high as $144.22 and last traded at $143.22, with a volume of 5118 shares traded. The stock had previously closed at $141.00.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Wells Fargo & Company reaffirmed an "overweight" rating and set a $160.00 target price on shares of Integer in a report on Tuesday, December 3rd. Piper Sandler restated an "overweight" rating and set a $140.00 price objective (up previously from $125.00) on shares of Integer in a report on Friday, October 25th. KeyCorp increased their target price on Integer from $139.00 to $144.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 15th. Benchmark boosted their price target on Integer from $130.00 to $140.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Finally, Bank of America increased their price objective on Integer from $135.00 to $145.00 and gave the stock a "buy" rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $145.44.

Integer Stock Up 1.5 %

The stock has a 50-day moving average of $136.56 and a 200 day moving average of $129.05. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09. The company has a market cap of $4.80 billion, a P/E ratio of 44.15, a PEG ratio of 1.80 and a beta of 1.12.

Integer (NYSE:ITGR - Get Free Report) last issued its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, beating the consensus estimate of $1.36 by $0.07. The company had revenue of $431.42 million during the quarter, compared to analysts' expectations of $440.59 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. The business's revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.27 EPS. Research analysts anticipate that Integer Holdings Co. will post 5.33 earnings per share for the current year.

Institutional Trading of Integer

Large investors have recently bought and sold shares of the business. American Century Companies Inc. lifted its holdings in shares of Integer by 249.7% in the second quarter. American Century Companies Inc. now owns 15,710 shares of the medical equipment provider's stock worth $1,819,000 after acquiring an additional 11,218 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in Integer by 9.0% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 30,771 shares of the medical equipment provider's stock valued at $3,563,000 after purchasing an additional 2,546 shares during the last quarter. Hsbc Holdings PLC lifted its stake in Integer by 123.3% in the 2nd quarter. Hsbc Holdings PLC now owns 6,458 shares of the medical equipment provider's stock valued at $745,000 after purchasing an additional 3,566 shares during the last quarter. XTX Topco Ltd acquired a new stake in Integer in the second quarter valued at approximately $596,000. Finally, Public Sector Pension Investment Board grew its stake in shares of Integer by 7.8% during the second quarter. Public Sector Pension Investment Board now owns 73,672 shares of the medical equipment provider's stock worth $8,530,000 after buying an additional 5,358 shares during the last quarter. 99.29% of the stock is owned by institutional investors and hedge funds.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.